Table 1.
CML and CEL plasma levels in 43 HCs and 99 MS patients stratified by disease stage.
| Groups | Gender | (n) | CML (ng/ml) | p value | CEL (ng/ml) | p value |
|---|---|---|---|---|---|---|
| HC | M+F | 43 | 309.5 ± 20(104-683) | 128.8 ± 12(17-259) | ||
| M | 11 | 379.7 ± 32(215-560) | 178.4 ± 16(49-258) | |||
| F | 32 | 285.4 ± 23(104-683) | 0.03 | 111.7 ± 14(17-259) | 0.02 | |
| MS | M+F | 99 | 306.4 ± 15 (117-911) | 231.7 ± 15(29-781) | ||
| M | 28 | 271.3 ± 17 (124-418) | 237.8 ± 44(29-781) | |||
| F | 71 | 319.2 ± 19 (117-911) | 0.1 | 225.8 ± 15(34-651) | 0.7 | |
| CIS | M+F | 7 | 336.5 ± 44(182-529) | 218.4 ± 79(42-502) | ||
| M | 4 | 317.2 ± 45 (182-372) | 171.5 ± 106(45-488) | |||
| F | 3 | 362.5 ± 95(197-529) | 0.6 | 281.0 ± 132(42-502) | 0.5 | |
| RRMS | M+F | 65 | 317.8 ± 17(140-869) | 246.3 ± 20(47-781) | ||
| M | 14 | 291.5 ± 21(145-418) | 305.2 ± 68(47-781) | |||
| F | 51 | 322.0 ± 22(140-869) | 0.4 | 229.1 ± 17(49-651) | 0.1 | |
| SPMS | M+F | 18 | 275.4 ± 52(117-911) | 195.9 ± 33(29-460) | ||
| M | 6 | 197.8 ± 28(124-271) | 164.1 ± 73(29-327) | |||
| F | 12 | 314.6 ± 75(117-911) | 0.3 | 206.5 ± 39(34-460) | 0.6 | |
| PPMS | M+F | 9 | 256.0 ± 20(151-362) | 196.9 ± 28(53-362) | ||
| M | 4 | 246.7 ± 46(151-362) | 238 ± 71(115-362) | |||
| F | 5 | 263.3 ± 22(217-334) | 0.7 | 205 ± 10(176-225) | 0.8 | |
| RRMS (clinically stable) | M+F | 49 | 302.9 ± 17(140-651) | 263.4 ± 25(47-781) | ||
| M | 13 | 293.6 ± 24(145-418) | 302.6 ± 79(47-781) | |||
| F | 36 | 308.5 ± 22(140-651) | 0.7 | 245.1 ± 21(49-651) | 0.3 | |
| RRMS (in clinical relapse) | M+F | 16 | 362.5 ± 42(158-869) | 196.6 ± 22(74-442) | ||
| M | 1 | 338.00 | 204.4 | |||
| F | 15 | 364.4 ± 45(158-869) | 196.1 ± 24(75-442) |
CML and CEL plasma levels in 43 HCs and 99 MS patients stratified by both disease stage and gender. The results are mean ± SEM and associated ranges. P values are related to gender differences in CML and CEL plasma levels. P value ≤ 0.05 is statistically significant.